300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
The Readout Loud
00:00
Challenges for Chinese CDMO Manufacturer under the BioSecure Act
The chapter explores the potential ramifications of the BioSecure Act on a Chinese CDMO manufacturer, Wushi, and its implications for the US pharmaceutical industry. It delves into the evolving regulatory landscape between China and the US, including mentions of President Biden's executive order and concerns over data security and ties to the Chinese government. Additionally, the chapter discusses the potential banning of Chinese companies like Wushi from operating in the US and the uncertainties this poses for both the company and American pharmaceutical firms.
Transcript
Play full episode
